ChiCTR-INR-16008616
尚未开始
/
/
/
2016-06-08
/
/
原發性鼻淚管阻塞
比較絲裂黴素C合併支架植入術與單純黏膜瓣保留鼻內鏡下淚囊鼻腔吻合術對原發性鼻淚管阻塞 的手術療效
比較絲裂黴素C合併支架植入術與單純黏膜瓣保留鼻內鏡下淚囊鼻腔吻合術對原發性鼻淚管阻塞 的手術療效
比較絲裂黴素C合併支架植入術與單純黏膜瓣保留鼻內鏡下淚囊鼻腔吻合術對原發性鼻淚管阻塞的手術療效.
随机平行对照
治疗新技术
Randomized
Single-blind
Research Grants Council
/
340
/
1990-01-01
1990-01-01
/
Adult >=18 years old and there is no maximum age limit; Primary acquired nasolacrimal duct obstruction (PANLDO) diagnosed by lacrimal irrigation and probing, confirmed intraoperatively after incision of lacrimal sac; Informed consent for operation, randomization and recording; Compliance to follow-up and treatment.;
请登录查看Pregnancy, lactation (contraindication for topical mitomycin C); Known allergy to mitomycin, cocaine, adrenaline, steroid, silicone material; Contraindications of endonasal DCR or inability to undergo nasal endoscopy; Acute (<3 months) or non-bacterial dacryocystitis e.g. tuberculosis, fungal or parasitic; Ipsilateral canalicular disorder e.g. obstruction, canaliculitis, canaliculocele, diverticulum; Ipsilateral recurrent NLDO or any prior lacrimal intervention except punctoplasty; Ipsilateral facial paralysis despite apparent clinical recovery; Ipsilateral conditions affecting bony nasolacrimal outflow e.g. midfacial trauma/fracture42, osteoma, fibrous dysplasia and other skull-base disorders; Ipsilateral suspected or confirmed nasolacrimal or sinoorbital neoplasm 43; Ipsilateral severe ocular surface disorders e.g. ocular cicatrical pemphigoid, chemical burns, Steven Johnson Syndrome, Toxic Epidermal Necrolysis44; Conditions affecting mucosa of the nose or nasolacrimal system e.g. rhinosinusitis, Wegener’s granulomatosis, sarcoidosis45, radioactive iodide46, head & neck radiotherapy47, ipsilateral maxillectomy48, systemic chemotherapy (5-fluorouracil, docetaxel49); Ipsilateral topical antiglaucomatous or chemotherapy drops (e.g. timolol50, mitomycin C); Intraoperative false passage of Bowman probe or metal part of silicone stent; Dacryolith or intrasaccal mass.;
请登录查看Research Grants Council
/
Research Grants Council的其他临床试验
- 促进香港新移民家庭心理社会调适:平行亲子正念干预的随机对照试验
- Enhancing global self-esteem of breast cancer survivors: a randomized controlled trial
- Mapping the Thyroid Associated Orbitopathy (TAO) Genes by Whole Genome Sequencing (WGS)
- Neurobiological mechanisms underlying the effects of mindfulness-based intervention and Tai Chi Chuan on sleep disturbance in older people
- Effectiveness of School-Based Mindfulness Intervention with Migrant Children in China: Building Resilience in an Under-Served Population
- Mechanisms involved in the effect of a brief mindfulness based intervention on personal recovery in people with bipolar disorder
- Can increasing participation in habitual intellectual activities enhance functional connectivity of default mode network in community-living Chinese adults with subjective cognitive decline? A randomized controlled trial.
- Retinal Nerve Fiber Layer Optical Texture Signature as a Novel Biomarker for Detection of Glaucoma Progression
- A randomised controlled trial for investigating the effectiveness of parent training on promoting physical activity in children with autism spectrum disorder
- 比較絲裂黴素C合併支架植入術與單純黏膜瓣保留鼻內鏡下淚囊鼻腔吻合術對原發性鼻淚管阻塞 的手術療效
- External cephalic version for breech presentation: A randomised controlled trial of anaesthetic interventions
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong的其他临床试验
- The effect of Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors on Diabetic Retinal Disease
- 利用下一代蛋白質組學技術鑑定淚膜中青光眼的生物標誌物
- 比較絲裂黴素C合併支架植入術與單純黏膜瓣保留鼻內鏡下淚囊鼻腔吻合術對原發性鼻淚管阻塞 的手術療效
- 低濃度阿托品眼藥水在近視發病預防之研究
- 比效玻璃體注射類固醇(triamcinolone acetonide)及抗血管內皮生長因子藥物(ranibizumab)聯合療法和單一注射抗血管內皮生長因子藥物(ranibizumab)治療新生血管老年性黃斑病變之療效及安全性的前膽性研究
- 對原發性開角型青光眼、原發性閉角型青光眼或高眼壓病人施用0.0015% Tafluprost(他氟前列素)滴眼液後的24小時眼球內壓概況的研究
最新临床资讯
-
飞眸医疗首例人体临床试验(FIH)成功开展,国产飞秒屈光设备竞逐540亿屈光市场
动脉网-最新2026-09-10
-
和铂医药:超长效靶向TSLP抗体哮喘二期临床取得阳性结果,三期临床已启动
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
动脉网-最新2026-09-09
-
药明康德2026-09-09
-
一度医药2026-09-08
-
阿斯利康中国2026-09-08
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-09-10
-
2026-09-09
-
2026-09-08
-
摩熵咨询 20 5
-
摩熵咨询 20 8
-
摩熵咨询 34 43
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构:国家医保局 2026-07-31
-
颁布机构:国家药品审评中心(CDE) 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-09-10
-
2026-09-10
-
2026-09-10
-
摩熵咨询 35 60
-
摩熵咨询 28 52
-
摩熵咨询 34 37
-
颁布机构:国家市场监督管理总局 2026-08-10
-
颁布机构:国家市场监督管理总局 2026-05-29
-
颁布机构:国家市场监督管理总局 2026-05-29

